Amedi.sk
Dovoľujeme si Vás upozorniť, že naša web stránka
je určená iba pre odbornú lekársku verejnosť.
Časopis Clinical urology – Článok Impact of absorbent products, duloxetine and a transobturator midurethral sling on quality-adjustelife years in women with stress urinary incontinence

Clinical urology

Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
Téma: 

Impact of absorbent products, duloxetine and a transobturator midurethral sling on quality-adjustelife years in women with stress urinary incontinence

Ján Švihra, Róbert Dušenka, Ján Ľupták, Igor Sopilko, Viera Švihrová

Objective: Stress urinary incontinence (SUI) is one of the most common dysfunctions of the lower urinary tract, and affects
patients’ quality of life. The principle of quality-adjusted life years (QALYs) was developed by the World Health Organization
(WHO) and the World Bank to enable reasonable health care. QALYs are calculated as the sum of the highest
quality of life years gained as a result of medical intervention. The aims of this study were to compare QALYs after
absorbent products, duloxetine and transobturator tape used in a group of women with SUI.
Materials and Methods: Women were included in the prospective study based on the following inclusion criteria: age higher
than 18 years, SUI, not using absorbent products or duloxetine and surgical treatment of SUI. Exclusion criteria were
urgency or neurogenic urinary incontinence, lower urinary tract cancer and urogenital fistulas. Women were evaluated after
three consecutive six-month periods. In the first period (PAD), incontinence absorbent products were used. In the second
period (Dx), a full titration oral dose (80 mg per day) of duloxetine was used. The third period (TOT) occurred after the
transobturator midurethral sling was implanted. The measurement included the International Consultation on Incontinence
Questionnaire-Urinary Incontinence Short Form (ICIQ-UI), on which, the total score ranges from 0 (without SUI) to
21 (the most severe SUI). The calculation of the weighting factor (WF) was obtained by linear transformation of the ICIQUI
total score as follows: 1 – ICIQ-UI total score/21. The QALYs was calculated as the WF x period of intervention.
Results: The study included 125 women, of whom, 102 were analysed (81.6%). All patients were Caucasian, with a mean
age of 53 years (range 26–69 years). In the PAD, mean ICIQ-UI score decreased from 18.3 to 14. 4. In the Dx, the average
score decreased from 16.9 to 11. 5. In the TOT, the mean score decreased from 17.2 to 1. 7. The WF changes after
the PAD was 0.2 ± 0.1, after the Dx, was 0.3 ± 0.2, and after the TOT was 0.7 ± 0. 1. The mean number of QALYs achieved
after the PAD was 0.16 ± 0.12, after the Dx, was 0.25 ± 0.13 and after the TOT was 0.46 ± 0.05 relative SUI. The changes
were statistically significant (p < 0.01).
Conclusions: All methods increased the number of QALYs. Incontinence absorbent products improved the quality of life
but not the degree of SUI, duloxetine improved the quality of life and decreased the level of SUI, and the transobturator
midurethral sling improved the quality of life and eliminated SUI.

Klin urol 2017; 13 (1): 41 – 45

Ročník 2017  Témy časopisu Clinical urology 1 / 2017

Nie sú dostupné žiadne voľne dostupné články
CHAIRMAN OF THE EDITORIAL BOARD
prof. MUDr. Ján Kliment, CSc.

MEMBERS OF THE EDITORIAL BOARD
prof. Andrzej Borówka, M.D., PhD.
prof. MUDr. Ján Breza, DrSc.
prof. MUDr. Peter Bujdák, PhD.
prof. MUDr. Tomáš Hanuš, DrSc.
doc. MUDr. Ladislav Jarolím, CSc.
doc. MUDr. Ján Ľupták, PhD.
doc. MUDr. Jozef Marenčák, PhD.
doc. MUDr. Ivan Minčík, PhD.
prof. MUDr. Dalibor Ondruš, DrSc.
prof. Imre Romics, M.D., PhD.
doc. MUDr. Vladimír Študent, PhD.
prof. MUDr. Ján Švihra, PhD.
prof. MUDr. Ladislav Valanský, PhD.
doc. MUDr. František Záťura, PhD.
MUDr. Peter Zvara, PhD.

PROFESSIONAL EDITOR
prof. MUDr. Ján Švihra, PhD.

EDITOR-IN-CHIEF
Ing. Danica Paulenová
e-mail: paulenova@amedi.sk

GRAPHIC LAYOUT AND TYPESETTING
Lucia Vecseiová
e-mail: dtp@amedi.sk

MARKETING MANAGER
Ing. Dana Chodasová
mobil: 0903 224 625
e-mail: marketing@amedi.sk

ECONOMY AND SUBSCRIPTIONS
Ing. Mária Štecková
telefón: 02/55 64 72 48
mobil: 0911 117 949
e-mail: ekonom@amedi.sk

LANGUAGE PROOFREADING
Mgr. Eva Doktorová

PROOFREADING OF ENGLISH TEXTS
Mgr. Jana Bábelová
SECTIONS

OVERVIEW PAPERS
The latest knowledge on disease and disease groups aetiology, pathogenesis, diagnoses and therapy. Maximum extent is 7 pages of text (font ARIAL or TIMES, font size 12, line spacing 1.5). In case of more extensive theme elaboration it is possible to divide the paper to several parts after agreement with editorial office.

ORIGINAL PAPERS
Structuring: introduction, clinical group and methods, results, discussion, conclusion, bibliography

DIAGNOSTIC AND THERAPEUTICAL ALGORITHMS
Diagnosis and therapy processed into tables and schemes, with minimum text, with emphasis on conciseness and clarity.

CASE STUDY
Maximum extent is 3 pages. Structuring: summary, case study, conclusion, bibliography.

MISCELLANEOUS
Reaction to overview articles, news in the field of diagnostics, therapy, trial results (maximum 3 pages), reports from professional events, abstracts from scientific work published abroad, not older than 1 year. Maximum extend is 1 page. Title of the paper in Slovak/Czech, authors, workplace, then title of the paper in English with full citation.


MANUSCRIPT ELABORATION

Write the paper on computer in any common text editor.
write full length of lines (do not use ENTER at the end of a line)
- do not arrange text into columns
- do not do page make-up, put tables at the end of the paper
- distinguish precisely numbers 1, 0 and letters l, O
- use always parentheses ( )
- explain abbreviations always when first used


MANUSCRIPT REQUIREMENTS

1. An accurate paper title, names and surnames of all authors including titles, authors` workplace. The first author address including the phone number, fax and e-mail address.
2. Summary - structured abstract: goal of work, material and methods (do not state the name of the workplace), results, conclusion
3. Key words - in the extent of 3-6.
Write in 1st or 3rd person singular or plural (unify according the type of an article).
4. English translation: the title of the paper, summary, key words 5. Text
If you insert pictures into a document, send also their original files in "jpg" format, create graphs in Excel and send also their original files. If you send photo documentation via post office, please, send just high-class originals. Mark each original by a number, under which it is mentioned in the text. Write in 1st or 3rd person singular or plural (unify according the type of an article). In the text do not use highlighting of the text as e.g. underlined text, bold, with exception of titles, references to pictures, tables, graphs.

6. Bibliography
Citations are numbered chronologically in bold, references in the text are stated by the number of citations in parentheses.
Citation means in general: the surname of the author (authors), title of the work, year of issuing, volume, pages.
Do not use "ét al.", but state all authors.

Examples of citations:
1. Shaheen NJ, Crosby NA, Bozymski EM, et al. Is there publication bias in the reporting cancer risk in Barrett´ esophagus? Gastroenterology 2000; 119: 333-338.
2. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Jurkovičová O, Spitzerová H, Cagáň S. Komorové arytmie a náhla srdcová smrť pri akútnom infarkte myokardu. Bratisl Lek Listy 1997; 98: 379-389.
5. Osborne BE. The electrocardiogram of the rat. In: Budden R, Detweiler DK, Zbinden G. The rat electrocardiogram in pharmacology and toxicology. Oxford: Pergamon Press 1981:15-27.

Do not use dots after first names in citations. Do not use colon but dot after names of authors. Use semi-colon after the year of publishing, colon is before pages.

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

Which of following factors is not related to rosacea?
a. genetic predisposition
b. Scandinavian origin
c. propionibacterium acnes
d. endothelial growth factor

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

All published papers are paid.

Send contributions in the e-mail to the address: paulenova@amedi.sk
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year